Hi June, Don, et al,
As part of the BioRDF's SenseLab task, we have recently created an RDFS
ontology for BrainPharm (a subdatabase of SenseLab). The ontology can be
used to model information about the effect of drugs on pathological (or
molecular) mechanisms (which involve neuronal properties such as
receptors, currents, and neurotransmitters) mediating the pathological
changes in various neurological disorders such as AD. For more
information, please go to the following wiki page:
http://esw.w3.org/topic/BrainPharm
I hope this ontology (with modifications/extensions perhaps) may be
useful to the AD use case.
Best,
-Kei
June Kinoshita wrote:
Thanks Don. I think we'll hunker down with the article for a while,
and if any questions come up, perhaps she could answer them via
email. That may be the most efficient way to proceed at this point.
Cheers,
June
On Jan 31, 2007, at 2:48 PM, Donald Doherty wrote:
Hi All,
Susan Catalano said she'd be happy to join one of the HCLSIG
teleconference
calls to answer questions about ADDL (if there is still a need).
Don
-----
Donald Doherty, Ph.D.
Brainstage Research, Inc.
www.brainstage.com
[EMAIL PROTECTED]
412-683-1410
